<DOC>
	<DOC>NCT02156297</DOC>
	<brief_summary>It is a prospective, non-interventional, open-label study, in order to observe the safety and response in FLT3-ITD mutation positive AML patients who receiving sorafenib as induction, consolidation, salvage, maintenance or alleviative treatment. The duration of the study from June 2014 through May 2019, with the recruitment duration from June 2014 to May 2017. The inclusion criteria is: 1. Definitely diagnosed as AML 2. FLT3-ITD mutation has been confirmed 3. Accepting the prescription of sorafenib</brief_summary>
	<brief_title>Sorafenib to Treat FLT3-ITD AML</brief_title>
	<detailed_description />
	<mesh_term>Leukemia, Myeloid, Acute</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<criteria>Definitely diagnosed as AML FLT3ITD mutation has been confirmed Accepting the prescription of sorafenib Can not take drugs orally Can not follow the doctors' advices Other reasons that investigators considered as contraindications for this study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>